|
|
|
|
|
|
|
CHEMICALS & PHARMACEUTICALS INDUSTRY NEWSLETTER
|
|
|
|
26 FEBRUARY 2017
|
|
|
|
|
|
|
|
|
The Winning Formula: Building the Number One Biopharmaceutical Supercluster
|
|
|
|
Massachusetts offers perhaps the most attractive environment for biopharmaceutical research and development in the world, and is fast closing the gap with its rival supercluster in California.
|
|
|
|
|
|
|
|
|
|
|
|
Introducing Brazil’s Chemical Sector
|
|
|
|
GBR investigates Brazil’s chemical sector amidst a period of political and economic instability.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Richard Pino, Vice President Sales and Marketing,
Latin America, Croda Do Brasil
|
|
|
|
"We have a strong product development pipeline at our Campinas site and want to grow through local production and better serving our local customers. We also want to grow above the level of economic growth in a sustainable way due to the benefits our ingredients offer in use and by continuing to improve the impact of our operations."
|
|
|
|
|
|
|
|
|
|
|
|
Richard Peters,
President and CEO, Merrimack Pharmaceuticals
|
|
|
|
"The source of the cancer in terms of the organ does not really matter; what really matters is what is making it grow. Now that we can better understand the science we can move towards more personalized treatments, which really interests investors."
|
|
|
|
|
|
|
|
|
|
|
|
Ankit Mahadevia, CEO and Cristina Larkin, Chief Commercial Officer, Spero Therapeutics
|
|
|
|
"Two factors drive resistance: overutilization and long links of usage for prolonged periods of time. While all drugs will eventually build a resistance, choosing the appropriate populations and using them in the right way helps to delay the onset of resistance. At the end of the day, as our CSO, Tom Parr, will say “The bugs will always win.” This is why it is so important to continue developing antibiotics and attempt to stay one step ahead of the bacteria."
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Biopharmaceuticals 2017
|
|
|
|
A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is framed by uncertainty in light of the country’s recent political transition. Nevertheless, the industry is robust and ready to adapt, already reacting to recent negative media attention relating to drug pricing and price increases. With an increasing amount of innovation stemming from small biotechnology companies and projects spun out from universities into start-ups, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
India Pharmaceuticals 2017
|
|
|
|
|
|
Taiwan Pharmaceuticals & Biotechnology 2015
|
|
|
|
|
|
Turkey Pharmaceuticals 2015
|
|
|
|
|
|
|
|
|
|
|
|
GBR has just launched the Industry Explorations report on the India Pharmaceutical industry, and we have a team in the United States to put together GBR’s 2018 U.S. Biopharmaceuticals report. If you are interested to take part in our research get in touch with us at chowe@gbreports.com for any questions or suggestions.
To access the full digital release of our report, please visit the Publications section of our website, gbreports.com for any questions or suggestions.
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Biopharmaceuticals, Peru Mining, Chile Mining
|
|
|
|
|
|
|
|
|
|
|
